Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of tisagenlecleucel in end-of-consolidation MRD-positive high-risk B-cell acute lymphoblastic leukemia
NL-OMON58765Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in acute lymphoblastic leukemia (ALL), sponsored by Novartis. Primary endpoints: 4-year overall survival rate and 5-year disease-free survival rate without censoring for new anticancer therapy. Started Nov 2019; status: active, not recruiting.
02
Drugs
tisagenlecleucel
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON58765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58765.